Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial - CNBC

By Anonymous User · February 23, 2026

Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly's in trial  CNBCNovo’s Next-Generation Obesity Shot Falls Short of Lilly Rival  BloombergNovo Nordisk's CagriSema trial deals a blow in obesity drug rivalry with Eli Lilly  ReutersNovo Nordisk pitted a new weight-loss drug against Eli Lilly’s — and lost  MarketWatchNovo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound  The Wall Street Journal